Recurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib

Bergman, Joel C.; Ly, Thai Yen; Keating, Margaret-Mary; Hull, Peter

doi:10.1177/1203475418775663

Cited by 7 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 23.3% incidence of rashes associated with dasatinib has been estimated. Most rashes were graded as mild, only 1.1% being high grade 10. Several authors have reported immune activation and peripheral T lymphocytosis associated with dasatinib treatment 11–13.…”

Section: Introductionmentioning

confidence: 97%

<p>Skin lesions in chronic myeloid leukemia patients during dasatinib treatment</p>

Tarantini

Anelli

Ingravallo

et al. 2019

CMAR

View full text Add to dashboard Cite

PurposeIn our work we sought to define the prevalence rates of cutaneous events during dasatinib therapy in chronic myeloid leukemia (CML) patients and to investigate the clinical and pathological characteristics of these reactions.Patients and methodsIn our institution, 67 CML patients were treated with dasatinib. it was given as first line treatment in 26 (39%) and subsequent treatment in 41 (61%) CML patients. Flow cytometry analysis of peripheral blood and cutaneous biopsy was done on all CML patients with dermatological lesions appearing during dasatinib treatment.ResultsAmong 67 CML patients, 4 (5.9%) showed skin lesions during dasatinib treatment. The cutaneous manifestations were not generalized but mainly located on the back, abdomen, thorax or leg regions. The patients did not show peripheral lymphocytosis at the time when skin lesions appeared. Overall, histological analysis showed that the skin lesions were characterized by a mild perivascular small CD8+ T lymphocytes infiltrate with minimal epidermotropism.ConclusionThe unusual T cytotoxic cutaneous infiltrate demonstrated in our CML cases could be the expression of a dasatinib-promoted lymphocyte expansion. However, the heterogeneity of the dermatologic manifestations reported in our CML patients could also be related to unknown factors specific to each CML patient. Our work highlights the finding that skin lesions may be associated with dasatinib treatment and that they should not be confused with viral or bacterial infections but rather interpreted as the clinical expression of lymphocytosis promoted by this TKI.

show abstract

Section: Introductionmentioning

confidence: 97%

<p>Skin lesions in chronic myeloid leukemia patients during dasatinib treatment</p>

Tarantini

Anelli

Ingravallo

et al. 2019

CMAR

View full text Add to dashboard Cite

show abstract

“…However, the term “neutrophilic fixed drug eruption” was chosen given the recurrent and fixed nature of the lesions clinically 5 . This constellation of findings has been subsequently reported in several other cases of neutrophilic FDE 6,7,9,20 . Conversely, a case showing the typical epidermal interface changes of classic FDE with an underlying inflammatory infiltrate containing neutrophils has also been reported 8 …”

Section: Discussionmentioning

confidence: 99%

“…A range of histopathologic features has been described including a neutrophilic inflammatory infiltrate that can be superficial or deep, interstitial or perivascular, and sometimes accompanied by leukocytoclasis, suggestive of a neutrophilic dermatosis. In addition, interstitial eosinophils, papillary dermal edema, and interface dermatitis have all been reported 5–8 . Exocytosis of neutrophils with intraepidermal pustule formation has been described 9 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neutrophilic fixed drug eruption, a histopathologic variant or an expected finding?—A report of two cases and review of the literature

et al. 2023

View full text Add to dashboard Cite

Fixed drug eruption (FDE) is an adverse drug reaction characterized by recurrent circumscribed lesions at the same location upon re-exposure to the culprit medication, resulting in distinct postinflammatory hyperpigmentation. Histopathologically, FDE demonstrates a predominantly lymphocytic interface or lichenoid infiltrate with basal cell vacuolar changes and keratinocyte dyskeratosis/apoptosis. The term "neutrophilic fixed drug eruption" has been used to describe cases in which the inflammatory infiltrate is predominantly neutrophilic. The infiltrate can extend deeper in the dermis, potentially mimicking a neutrophilic dermatosis such as Sweet syndrome.We present two cases and review the literature to discuss the possibility that a neutrophilic inflammatory infiltrate may be an expected finding in FDE, rather than a histopathologic variant.

show abstract

Dasatinib

2019

Reactions Weekly

View full text Add to dashboard Cite

Recurrent and Fixed Neutrophilic Dermatosis Associated With Dasatinib

Abstract: This report extends the clinical spectrum of neutrophilic dermatoses to include dasatinib-induced recurrent and fixed erythematous plaques.

Cited by 7 publications

References 16 publications

<p>Skin lesions in chronic myeloid leukemia patients during dasatinib treatment</p>

<p>Skin lesions in chronic myeloid leukemia patients during dasatinib treatment</p>

Neutrophilic fixed drug eruption, a histopathologic variant or an expected finding?—A report of two cases and review of the literature

Dasatinib

Contact Info

Product

Resources

About